Aclaris Therapeutics (ACRS) Enterprise Value (2014 - 2026)

Aclaris Therapeutics' Enterprise Value history runs 13 years deep, the most recent figure standing at -$105.4 million for Q1 2026.

• On a quarterly basis, Enterprise Value changed 0.1% year-over-year to -$105.4 million in Q1 2026; TTM through Mar 2026 was -$105.4 million, a 0.1% change from a year earlier, with the FY2025 full-year figure at -$90.8 million, up 20.11% from the prior year.
• Enterprise Value slipped to -$105.4 million in Q1 2026 per ACRS's latest filing, from -$90.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$90.8 million in Q4 2025 and bottomed at -$248.6 million in Q2 2022.
• The 5-year median for Enterprise Value is -$119.1 million (2023), against an average of -$140.3 million.
• Across the five-year window, Enterprise Value slumped 40.01% in 2022 and jumped 58.46% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$217.6 million in 2022, then surged by 45.26% to -$119.1 million in 2023, then grew by 4.63% to -$113.6 million in 2024, then increased by 20.11% to -$90.8 million in 2025, then decreased by 16.16% to -$105.4 million in 2026.
• Per Business Quant, the three latest ACRS Enterprise Value figures stand at -$105.4 million (Q1 2026), -$90.8 million (Q4 2025), and -$95.9 million (Q3 2025).